LINC02111: A Long Intergenic Non-Protein-Coding RNA (G401177)

Target Name: LINC02111

NCBI ID: G401177

LINC02111

Other Name(s): Long intergenic non-protein coding RNA 2111 | CTD-2139B15.4 | long intergenic non-protein coding RNA 2111

LINC02111: A Long Intergenic Non-Protein-Coding RNA

LINC02111 is a long non-coding RNA (lncRNA) that has been identified in various organisms, including humans. It is characterized by its ability to interact with proteins and other non-protein molecules, making it a potential drug target or biomarker.

Expression and Functions

LINC02111 is a highly expressed gene in the human body, with the highest expression levels in the brain. It is expressed in various cell types, including neurons, astrocytes, and endothelial cells. It has been shown to be involved in cell signaling, specifically in the regulation of cell adhesion and migration.

One of the most interesting features of LINC02111 is its ability to interact with several protein molecules. It has been shown to interact with the protein SMY3, which is involved in the regulation of stem cell self-renewal and differentiation. It also interacts with the protein ZNF2, which is involved in the regulation of gene expression and cell growth.

Another interesting feature of LINC02111 is its ability to form a complex with the protein JNJ116547, a known regulator of DNA binding proteins. This complex has been shown to play a role in the regulation of gene expression and DNA replication.

Drug Target Potential

LINC02111's ability to interact with multiple protein molecules makes it a promising drug target. The regulation of cell adhesion and migration is a key aspect of many diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. By targeting LINC02111, researchers may be able to develop new treatments for these diseases.

One potential approach to targeting LINC02111 is to use small molecules to interact with its interactors, such as SMY3 and ZNF2. This would involve modifying the activity of these proteins, potentially leading to the inhibition of their functions. Alternatively, LINC02111 could be targeted using RNA-based therapies, such as small interfering RNA (siRNA) or RNA-protein hybrids.

Biomarker Potential

LINC02111 has also been identified as a potential biomarker for several diseases. Its regulation of cell adhesion and migration makes it an attractive candidate for the diagnosis and prognosis of diseases characterized by these processes, such as cancer, neurodegenerative diseases, and autoimmune diseases.

In addition, LINC02111's regulation of stem cell self-renewal and differentiation may also be relevant to the diagnosis and treatment of diseases that involve stem cells, such as regenerative medicine and tissue engineering.

Conclusion

LINC02111 is a long non-coding RNA that has been identified in various organisms, including humans. Its ability to interact with multiple protein molecules makes it a potential drug target or biomarker. The regulation of cell adhesion and migration, as well as its ability to form complex with known regulators, make it an attractive candidate for targeting with small molecules or RNA-based therapies. Further research is needed to determine its potential as a drug target or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2111

The "LINC02111 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02111 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets